 |
|
Use of Hyaluronidase by Iontophoresis in Treatment of Lymphedema
M. STEPHEN SCHWARTZ, M.D.
AMA Arch Intern Med. 1955;95(5):662-668.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
Lymphedema is a swelling of soft tissues, the result of accumulation of increased quantities of lymph. A useful clinical classification by Allen, Barker, and Hines,1 modified by Duryee,* divides all cases into two main groups; inflammatory and noninflammatory.
- Noninflammatory
- Primary
- Congenital lymphedema
- Hereditary or familial (Milroy's disease)
- Lymphedema praecox
- Secondary
- Malignant occlusion
- Surgical removal of lymph nodes
- Pressure
- Radiation therapy
- Venous insufficiency
- Inflammatory
- Primary (single or recurrent acute and chronic)
- Secondary (single or recurrent acute and chronic)
- Trichophytosis
- Systemic disease
- Local tissue injury or inflammation
- Filariasis
Lymphedema has been poorly responsive to numerous forms of treatment short of extensive surgery. For this reason, any method which might promise some improvement of the frequently disabling and disfiguring features of this condition, and which is clinically feasible, should be investigated.
Hyaluronidase, the "spreading factor," was first described in 1929 by Duran-Reynals.2 Additional knowledge of its biological significance was contributed by
. . . [Full Text PDF of this Article]
Author Affiliations
New York
From the Department of Medicine, New York University Post-Graduate Medical School, University Hospital, and the Fourth (N. Y. U.) Medical Division, Bellevue Hospital.
Footnotes
The hyaluronidase used in this study was provided as Wydase by Wyeth Laboratories, Inc., Philadelphia.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
